Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific GLL-1 targeted antibody-drug conjugate
- Development stage
- Preclinical
- Lead developer
- Salubris Biotherapeutics Inc
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Bispecific GLL-1 targeted antibody-drug conjugate is an experimental oncology therapeutic being developed by Salubris Biotherapeutics. This candidate is a bispecific antibody-drug conjugate (ADC) that targets GLL-1, an antigen associated with cancer cells. By utilizing a bispecific format, the drug is designed to bind with high specificity to its target, subsequently internalizing to release a cytotoxic payload directly within the malignant cells. This mechanism aims to provide potent anti-tumor activity while minimizing damage to healthy tissues. The program is currently in the discovery phase of development, and specific details regarding the payload and linker chemistry have not yet been publicly disclosed.
- Other names
- GLL-1-ADCGLL1-ADCGLL 1-ADCbispecific GLL-1 targeted ADC
02
Targets
Beyond the preview
Go deeper on bispecific GLL-1 targeted antibody-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific GLL-1 targeted antibody-drug conjugate.